Raras
Buscar doenças, sintomas, genes...
Cistinose
ORPHA:213CID-10 · E72.0CID-11 · 5C60.1DOENÇA RARA

A cistinose é uma doença metabólica que se caracteriza pelo acúmulo de uma substância chamada cistina dentro dos lisossomos (estruturas localizadas nas células). Esse acúmulo causa danos em diversos órgãos e tecidos, especialmente nos rins e olhos. Foram descritas três formas clínicas: a nefropática infantil, a nefropática juvenil e a ocular.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A cistinose é uma doença metabólica que se caracteriza pelo acúmulo de uma substância chamada cistina dentro dos lisossomos (estruturas localizadas nas células). Esse acúmulo causa danos em diversos órgãos e tecidos, especialmente nos rins e olhos. Foram descritas três formas clínicas: a nefropática infantil, a nefropática juvenil e a ocular.

Pesquisas ativas
14 ensaios
46 total registrados no ClinicalTrials.gov
Publicações científicas
1.612 artigos
Último publicado: 2026 Mar 31
Medicamentos
1 registrados
ELX-02

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
ELX-02

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.5
Europe
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: E72.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (7)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)nutritional
0301070040
Atendimento em reabilitação — doenças raras
+1 outros procedimentos
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫘
Rins
20 sintomas
📏
Crescimento
15 sintomas
🧠
Neurológico
12 sintomas
👁️
Olhos
11 sintomas
🦴
Ossos e articulações
8 sintomas
🫃
Digestivo
7 sintomas

+ 45 sintomas em outras categorias

Características mais comuns

90%prev.
Disfunção tubular renal
Muito frequente (99-80%)
90%prev.
Nefropatia
Muito frequente (99-80%)
90%prev.
Baixa estatura
Muito frequente (99-80%)
90%prev.
Déficit de crescimento
Muito frequente (99-80%)
90%prev.
Hipofosfatemia
Muito frequente (99-80%)
90%prev.
Aminoacidúria
Muito frequente (99-80%)
127sintomas
Muito frequente (21)
Frequente (18)
Ocasional (17)
Sem dados (71)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 127 características clínicas mais associadas, ordenadas por frequência.

Disfunção tubular renalRenal tubular dysfunction
Muito frequente (99-80%)90%
NefropatiaNephropathy
Muito frequente (99-80%)90%
Baixa estaturaShort stature
Muito frequente (99-80%)90%
Déficit de crescimentoFailure to thrive
Muito frequente (99-80%)90%
HipofosfatemiaHypophosphatemia
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.612PubMed
Últimos 10 anos200publicações
Pico202455 papers
Linha do tempo
2026Hoje · 2026🧪 1979Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

CTNSCystinosinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cystine/H(+) symporter that mediates export of cystine, the oxidized dimer of cysteine, from lysosomes (PubMed:11689434, PubMed:15128704, PubMed:18337546, PubMed:22232659, PubMed:29467429, PubMed:33208952, PubMed:36113465). Plays an important role in melanin synthesis by catalyzing cystine export from melanosomes, possibly by inhibiting pheomelanin synthesis (PubMed:22649030). In addition to cystine export, also acts as a positive regulator of mTORC1 signaling in kidney proximal tubular cells, v

LOCALIZAÇÃO

Lysosome membraneMelanosome membraneCell membrane

VIAS BIOLÓGICAS (2)
Miscellaneous transport and binding eventsSLC-mediated transport of oligopeptides
MECANISMO DE DOENÇA

Cystinosis, nephropathic type

A form of cystinosis, a lysosomal storage disease due to defective transport of cystine across the lysosomal membrane. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. The classical nephropathic form has onset in the first year of life and is characterized by a polyuro-polydipsic syndrome, marked height-weight growth delay, generalized impaired proximal tubular reabsorptive capacity, with severe fluid-electrolyte balance alterations, renal failure, ocular symptoms and other systemic complications.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
48.4 TPM
Nervo tibial
37.2 TPM
Cervix Endocervix
29.4 TPM
Cervix Ectocervix
28.7 TPM
Ovário
24.3 TPM
OUTRAS DOENÇAS (4)
juvenile nephropathic cystinosisnephropathic cystinosisocular cystinosisnephropathic infantile cystinosis
HGNC:2518UniProt:O60931

Medicamentos e terapias

ELX-02Phase 2

Mecanismo: 80S Ribosome modulator

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

702 variantes patogênicas registradas no ClinVar.

🧬 CTNS: NM_004937.3(CTNS):c.329+16G>C ()
🧬 CTNS: NM_004937.3(CTNS):c.348T>G (p.Leu116=) ()
🧬 CTNS: NM_004937.3(CTNS):c.226-14A>G ()
🧬 CTNS: NM_004937.3(CTNS):c.972C>G (p.Asp324Glu) ()
🧬 CTNS: NM_004937.3(CTNS):c.971-17C>G ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 851 variantes classificadas pelo ClinVar.

213
340
298
Patogênica (25.0%)
VUS (40.0%)
Benigna (35.0%)
VARIANTES MAIS SIGNIFICATIVAS
CTNS: NM_004937.3(CTNS):c.1015G>C (p.Gly339Arg) [Pathogenic]
CTNS: NM_004937.3(CTNS):c.926del (p.Gly309fs) [Pathogenic]
CTNS: NM_004937.3(CTNS):c.925G>A (p.Gly309Ser) [Pathogenic]
CTNS: NM_004937.3(CTNS):c.1013T>G (p.Leu338Arg) [Pathogenic]
CTNS: NM_004937.3(CTNS):c.970+2T>C [Pathogenic]

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 25
·Pré-clínico15
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Cistinose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

13 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

46 ensaios clínicos encontrados, 14 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
527 papers (10 anos)
#1

A Refined Method for Micro-Scale Blood Cystine Measurement in Preclinical Cystinosis Models.

International journal of molecular sciences2026 Feb 08

Cystinosis is a rare autosomal recessive lysosomal storage disorder that is caused by mutations in the CTNS gene. The hallmark of this disease is the accumulation of cystine within lysosomes, which functions as a pivotal diagnostic and monitoring biomarker. Cysteamine therapy has been demonstrated to reduce lysosomal cystine and improve outcomes; however, it does not fully halt progression, particularly renal decline. Consequently, preclinical research relies on diverse in vitro and in vivo models to explore mechanisms and test new treatments. Accurate intracellular cystine quantification is vital for clinical and research purposes. Conventional granulocyte cystine measurement, the prevailing standard, is technically intricate and necessitates volumes of samples, which presents challenges for rodent models. Advancements in analytical chemistry, such as the use of liquid chromatography with tandem mass spectrometry (LC-MS/MS), have enhanced the sensitivity of analytical methods. However, the development of optimized methods for analyzing small volumes of biological samples remains a limitation. This study presents a novel micro-quantification protocol for measuring cystine in a minimal volume of whole blood from rodent models. This protocol enhances the sensitivity, reproducibility, and feasibility of longitudinal studies. Addressing this methodological gap is imperative for accelerating translational research and supporting the development of improved therapies for cystinosis.

#2

Advances in Pharmacological Treatments for Cystinosis: Cysteamine and Its Alternatives.

ACS pharmacology &amp; translational science2026 Feb 13

Cystinosis is an inherited lysosomal storage disorder characterized by the intralysosomal accumulation of crystals of cystine. This alteration is caused by the absence of the lysosomal membrane transporter cystinosin, which leads to clinical manifestations of the disease. Oral administration of aminothiol cysteamine, while not a curative therapy, has proven to be effective in controlling the progress of the disease and reducing its complications. However, the numerous side effects inherent to the treatment are responsible for low patient compliance, severely impacting therapy success. Several studies have been performed in the past few years with the aim of optimizing cysteamine therapy to avoid its main drawbacks. This review focuses on the potential and feasibility of these novel strategies. As well, it introduces novel recent approaches studied as an alternative or complement to cysteamine treatment.

#3

Hematopoietic Stem-Cell Gene Therapy for Cystinosis.

The New England journal of medicine2026 Feb 19

Cystinosis is a multisystemic lysosomal storage disorder caused by pathogenic variants in CTNS, the gene encoding cystinosin, a lysosomal transmembrane cystine transporter. In patients with cystinosis, cystine accumulates within lysosomes in all organs. The cystine-depleting agent cysteamine delays but does not prevent disease progression. In this phase 1-2, open-label, ongoing clinical study, we performed a preliminary assessment of CTNS-RD-04, which consists of autologous CD34+ cells transduced with lentiviral vectors carrying CTNS complementary DNA, in patients with cystinosis. The primary end points were the safety and the side-effect profiles of CTNS-RD-04. Secondary end points were measures of efficacy, including white-cell cystine levels and cystine storage depletion. Oral cysteamine was withdrawn before CTNS-RD-04 infusion, and cysteamine eyedrops were withdrawn 1 month after myeloablation. Six participants (20 to 46 years of age) received CTNS-RD-04 and were followed for 29 to 63 months. CTNS-RD-04 doses ranged from 3.63×106 to 9.59×106 CD34+ cells per kilogram of body weight, and vector copy numbers ranged from 0.59 to 2.91 copies per diploid genome. All the patients had sustained and highly polyclonal hematopoietic reconstitution; vector copy numbers at 24 months ranged from 0.51 to 2.67 copies per diploid genome. A total of 217 adverse events occurred, most of which were mild or moderate in severity and largely consistent with the procedures and underlying disease. No evidence of monoclonal expansion was noted. White-cell cystine levels decreased from baseline except in Patient 4, who had the lowest vector copy number. In this small study, CTNS-RD-04, an ex vivo gene therapy for cystinosis, had adverse effects that were largely consistent with the myeloablative regimen and underlying disease profile. White-cell cystine levels decreased after therapy. (Funded by the California Institute for Regenerative Medicine and others; ClinicalTrials.gov number, NCT03897361.).

#4

Cystinosis and Cellular Energy Failure: Mitochondria at the Crossroads.

International journal of molecular sciences2026 Jan 08

Cystinosis is a rare lysosomal storage disorder characterized by defective cystine transport and progressive multi-organ damage, with the kidney being the primary site of pathology. In addition to the traditional perspective on lysosomal dysfunction, recent studies have demonstrated that cystinosis exerts a substantial impact on cellular energy metabolism, with a particular emphasis on oxidative pathways. Mitochondria, the central hub of ATP production, exhibit structural abnormalities, impaired oxidative phosphorylation, and increased reactive oxygen species. These factors contribute to proximal tubular cell failure and systemic complications. This review highlights the critical role of energy metabolism in cystinosis and supports the emerging idea of organelle communication. A mounting body of evidence points to a robust functional and physical association between lysosomes and mitochondria, facilitated by membrane contact sites, vesicular trafficking, and signaling networks that modulate nutrient sensing, autophagy, and redox balance. Disruption of these interactions in cystinosis leads to defective mitophagy, accumulation of damaged mitochondria, and exacerbation of oxidative stress, creating a vicious cycle of energy failure and cellular injury. A comprehensive understanding of these mechanisms has the potential to reveal novel therapeutic avenues that extend beyond the scope of cysteamine, encompassing strategies that target mitochondrial health, enhance autophagy, and restore lysosome-mitochondria communication.

#5

Genetic predisposition to porto-sinusoidal vascular disorder.

Hepatology (Baltimore, Md.)2026 Feb 01

Porto-sinusoidal vascular disorder (PSVD) is a rare liver disease. The pathophysiological mechanisms underlying the development of PSVD are unknown. Isolated cases of PSVD associated with gene mutations have been reported, but no overview is available. Therefore, we performed an extensive literature search to provide a comprehensive overview of gene mutations associated with PSVD. We identified 34 genes and 1 chromosomal abnormality associated with PSVD in the literature, and we describe here 1 additional gene mutation ( TBL1XR1 mutation, leading to Pierpont syndrome). These gene mutations are associated either with extrahepatic organ involvement as part of syndromes (Adams-Oliver, telomere biology disorders, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations, immune deficiencies, cystic fibrosis, cystinosis, Williams-Beuren, Turner, Pierpont) or with isolated PSVD ( KCNN3 , DGUOK , FOPV , GIMAP5 , FCHSD1 , TRMT5 , HRG gene mutations). Most of the cases were revealed by signs or complications of portal hypertension. When analyzing the cell types in which these genes are expressed, we found that these genes are predominantly expressed in immune cells, suggesting that these cells may play a more important role in the development of PSVD than previously thought. In addition, pathway analyses suggested that there may be 2 types of PSVD associated with gene mutations: those resulting directly from morphogenetic abnormalities and those secondary to immune changes.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.215 artigos no totalmostrando 196

2026

Cystinosin regulates Na+/H+ exchanger 3 trafficking and function in kidney proximal tubular cells.

EMBO reports
2026

Cystinosin/Ers1 functions in redox homeostasis in the early secretory pathway.

bioRxiv : the preprint server for biology
2026

Successful Surgical Sperm Extraction in a Patient With Cystinosis.

Cureus
2026

A Refined Method for Micro-Scale Blood Cystine Measurement in Preclinical Cystinosis Models.

International journal of molecular sciences
2026

Molecular characterization of cystinosis patients: predominance of the CTNS c.829dup mutation in Center of Tunisia.

BMC genomic data
2026

Advances in Pharmacological Treatments for Cystinosis: Cysteamine and Its Alternatives.

ACS pharmacology &amp; translational science
2026

Gene Therapy for Nephropathic Cystinosis.

The New England journal of medicine
2026

Hematopoietic Stem-Cell Gene Therapy for Cystinosis.

The New England journal of medicine
2026

Comprehensive Ocular Characteristics in Cystinosis after Hematopoietic Stem-Cell Gene Therapy Over 24 Months.

American journal of ophthalmology
2026

Cystinosis and Cellular Energy Failure: Mitochondria at the Crossroads.

International journal of molecular sciences
2026

Improving Lifelong Comprehensive Care Coordination in Nephropathic Cystinosis: Multidisciplinary Perspectives.

Kidney international reports
2026

Cysteamine-eluting contact lenses: integrating in vitro, in vivo, and in silico approaches for ocular drug delivery.

International journal of pharmaceutics
2025

Cystinosis is Associated with Deficits in Muscle Mass, Strength and Hip Bone Density in Children and Young Adults.

Kidney360
2026

Nephropathic cystinosis: fibrosing colonopathy can also be seen long after introduction of delayed release cysteamine.

Pediatric nephrology (Berlin, Germany)
2025

Shimmering Clarity: A Rare Case Report of Ocular Cystinosis.

Case reports in ophthalmology
2025

Microgliopathy as a primary mediator of neuronal death in models of Friedreich's Ataxia.

Nature communications
2025

An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

Journal of cachexia, sarcopenia and muscle
2025

Gene Therapies: Any Merit in Nephrology?

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
2025

Introducing the University of California, Irvine Corneal Cystine Crystal Score: A Novel Tool for Assessing Corneal Crystal Deposition in Cystinosis Patients.

Scientific reports
2025

The assessment and treatment of the musculoskeletal manifestations of cystinosis.

Frontiers in nephrology
2025

Neuroretinal structure changes in infantile nephropathic cystinosis.

Orphanet journal of rare diseases
2025

Phenotypic variability in cystinosis: Lessons from an atypical case.

Nefrologia
2025

From Molecular Understanding and Pathophysiology to Disease Management; A Practical Approach and Guidance to the Management of the Ocular Manifestations of Cystinosis.

International journal of molecular sciences
2025

CRISPR and gene editing for kidney diseases: where are we?

Clinical kidney journal
2025

Genome-wide DNA methylation analysis identifies kidney epigenetic dysregulation in a cystinosis mouse model.

Frontiers in cell and developmental biology
2025

Therapeutic strategies in cystinosis: A focus on cysteamine and beyond.

Experimental and molecular pathology
2025

Cystadrops® Eye Drops for the Management of Ocular Cystinosis in Patients Aged 6 Months to < 2 Years.

Ophthalmology and therapy
2025

Diagnosis and management of cystinosis: systematic review for a clinical practice guideline.

Orphanet journal of rare diseases
2025

Local Guidance on the Management of Nephropathic Cystinosis in the Gulf Cooperation Council (GCC) Region.

Children (Basel, Switzerland)
2026

Ocular manifestations and multimodal imaging in infantile nephropathic cystinosis.

QJM : monthly journal of the Association of Physicians
2025

Serum N-glycosylation is altered in Nephropathic Cystinosis.

Glycobiology
2025

A puzzling renal Fanconi syndrome.

Clinical kidney journal
2026

Nasopharyngeal Cystine Crystal Deposition Postrenal Transplant: Case Report and Review of a Rare Cystinosis Manifestation.

International journal of surgical pathology
2025

Cystinosis symposium: a rare disease model for comprehensive care.

Frontiers in pediatrics
2025

Enhancing Cystinosis Health Care Transition Outcomes: Insights from the RISE Protocol.

Kidney international reports
2025

JIP4 deficiency causes a lysosomal storage disease arising from impaired cystine efflux.

bioRxiv : the preprint server for biology
2025

Transition from pediatric to adult nephropathic cystinosis care: the structure, challenges and lessons learned.

Frontiers in pediatrics
2025

Hypothesis: Taurine therapy of nephropathic cystinosis may correct the deficiencies of cysteamine therapy.

Molecular genetics and metabolism reports
2025

Perspectives: Mental health challenges and medical trauma: focus on cystinosis patients and caregivers.

Frontiers in pediatrics
2025

Nutrition across the Entire Lifespan in CKD: From Childhood to Senescence.

Clinical journal of the American Society of Nephrology : CJASN
2025

The Use of a Viscous Cysteamine Eyedrop in a Belgian Cohort: Early 3-Year Results.

Ophthalmology and therapy
2025

Emerging therapeutic strategies for cystinosis.

Frontiers in pediatrics
2025

Neurological involvement in 51 cystinosis patients: A single-center experience.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Pediatric cystinosis: Corneal cystine deposits and papilledema in a 4-year-old:  A case report.

Medicine international
2025

Untangling Traffic Jams: RAB11FIP4 Orchestrates Cellular Recovery in Cystinosis.

Autophagy reports
2025

Computational prediction of deleterious nonsynonymous SNPs in the CTNS gene: implications for cystinosis.

BMC genomic data
2026

Long-term outcomes in nephropathic cystinosis: a review.

Pediatric nephrology (Berlin, Germany)
2025

Drug-induced acute pancreatitis following dose increase of mycophenolate mofetil in a kidney transplant recipient: A case report and literature review.

Transplant immunology
2025

Advancing precision care in pregnancy through a treatable fetal findings list.

American journal of human genetics
2025

Native kidney and graft survival in a cohort of Egyptian children with nephropathic cystinosis: national referral center experience.

Italian journal of pediatrics
2025

Prospective Dysphagia Assessment in Adult Patients With Nephropathic Cystinosis.

Muscle &amp; nerve
2025

Impact of Early Versus Late Diagnosis on Disease Progression in Cystinosis.

Kidney international reports
2025

Transitioning Care in Nephropathic Cystinosis: Overcoming Challenges in Young Adults.

Kidney international reports
2025

Optimizing Long-Term Outcomes in Cystinosis With Comprehensive Patient-Centered Care.

Kidney international reports
2025

Addressing the Multisystemic Impacts of Nephropathic Cystinosis in an Adult.

Kidney international reports
2025

Transplantation of Wild-Type Hematopoietic Stem and Progenitor Cells Improves Disease Phenotypes in a Mucopolysaccharidosis IIIC Mouse Model.

Cell transplantation
2025

Novel mechanism for tubular injury in nephropathic cystinosis.

eLife
2025

Cystinosin is involved in Na+/H+ Exchanger 3 trafficking in the proximal tubular cells: new insights in the renal Fanconi syndrome in cystinosis.

bioRxiv : the preprint server for biology
2025

Targeting oxidative stress-induced lipid peroxidation enhances podocyte function in cystinosis.

Journal of translational medicine
2025

Brainstem Substructure Atrophy in Late-Onset GM2-Gangliosidosis Imaging Using Automated Segmentation.

Cerebellum (London, England)
2025

Adherence to delayed-release cysteamine in nephropathic cystinosis over time: data from the prospective CrYSTobs cohort study.

Pediatric nephrology (Berlin, Germany)
2025

Artificial intelligence enhanced microfluidic system for multiplexed point-of-care-testing of biological thiols.

Talanta
2025

Nexinhib20 inhibits JFC1-mediated mobilization of a subset of CD11b/CD18+ vesicles decreasing integrin avidity, but does not inhibit Rac1.

Journal of leukocyte biology
2025

Etiology, clinical characteristics, genetic profile, and outcomes of children with refractory rickets at a referral center in India: a cohort study.

Pediatric nephrology (Berlin, Germany)
2025

Theranostic Contact Lens for Ocular Cystinosis Utilizing Gold Nanoparticles.

Biosensors
2025

Liver Transplant From a Deceased Donor With Cystinosis: A Case Report.

JIMD reports
2024

Patient journey in cystinosis: focus on non-adherence and disease management.

Drugs in context
2025

Ocular Cystinosis Experience in Southwestern Ontario.

Journal of pediatric ophthalmology and strabismus
2024

An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients.

Clinical ophthalmology (Auckland, N.Z.)
2024

Characteristics of Inherited Metabolic Disorders Following Kidney Transplantation: A 13-Year Observational Study.

Medicina (Kaunas, Lithuania)
2024

A Modular Genetic Approach to Newborn Screening from Spinal Muscular Atrophy to Sickle Cell Disease-Results from Six Years of Genetic Newborn Screening.

Genes
2024

Cystinosis metabolic bone disease: inflammatory profile in human peripheral blood mononuclear cells and derived osteoclasts.

European journal of pediatrics
2024

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.

Frontiers in immunology
2024

Ocular Involvement in Infantile Cystinosis: A Case Report.

Cureus
2024

ZenoSWATH DIA proteomics and clustering analysis of the effect of cysteamine at the cellular level in cystinotic fibroblasts.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2024

Quality of life and mental health status in caregivers of pediatric patients with nephropathic cystinosis.

Orphanet journal of rare diseases
2024

Reconstitution of Rab11-FIP4 Expression Rescues Cellular Homeostasis in Cystinosis.

Molecular and cellular biology
2024

Mitigative role of cysteamine against unilateral renal reperfusion injury in Wistar rats.

Frontiers in pharmacology
2025

Evaluation of a new classification system for measuring the progression of ocular cystinosis: an analysis of 64 patients.

The British journal of ophthalmology
2024

Let Food Be Thy Medicine: Potential of Dietary Management in Cystinosis.

Journal of the American Society of Nephrology : JASN
2024

Severe pancytopenia at the presentation of Imerslund-Gräsbeck syndrome in a 23-month-old Italian boy.

Italian journal of pediatrics
2024

Leptin signalling altered in infantile nephropathic cystinosis-related bone disorder.

Journal of cachexia, sarcopenia and muscle
2024

Ocular Involvement in Patients with Infantile Nephropathic Cystinosis.

Turkish journal of ophthalmology
2024

Development and Evaluation of Different Electrospun Cysteamine-Loaded Nanofibrous Webs: A Promising Option for Treating a Rare Lysosomal Storage Disorder.

Pharmaceutics
2024

Adherence to Cysteamine Therapy Among Patients Diagnosed with Cystinosis in Saudi Arabia: A Prospective Cohort Study.

Pharmacy (Basel, Switzerland)
2024

Intermediate cystinosis: a case report of 10-year treatment with cysteamine.

BMC nephrology
2024

Perspectives from cystinosis: access to healthcare may be a confounding factor for variant classification.

Frontiers in genetics
2024

[Kidney involvement in rare hereditary diseases].

Terapevticheskii arkhiv
2024

Long-term effects of luteolin in a mouse model of nephropathic cystinosis.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2024

Chronic Kidney Disease and Growth Failure in Children.

Children (Basel, Switzerland)
2024

Failure to Thrive With Severe Hypokalemia Yields Cystinosis Diagnosis in a 19-Month-Old Female Child: A Case Report.

Cureus
2025

Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T.

The Journal of clinical endocrinology and metabolism
2024

Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2024

Ketogenic Diet and Progression of Kidney Disease in Animal Models of Nephropathic Cystinosis.

Journal of the American Society of Nephrology : JASN
2026

Genetic predisposition to porto-sinusoidal vascular disorder.

Hepatology (Baltimore, Md.)
2024

Cysteamine Suppresses Cancer Cell Invasion and Migration in Glioblastoma through Inhibition of Matrix Metalloproteinase Activity.

Cancers
2024

Cysteamine toxicity presenting with acute encephalopathy and spastic tetraparesis.

Practical neurology
2024

Cortical impairment and reduced muscle mass in children and young adults with nephropathic cystinosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2024

Morphological changes and their associations with clinical parameters in children with nephropathic cystinosis and chronic kidney disease prior to kidney replacement therapy over 25 years.

Pediatric nephrology (Berlin, Germany)
2024

A New and Rapid LC-MS/MS Method for the Determination of Cysteamine Plasma Levels in Cystinosis Patients.

Pharmaceuticals (Basel, Switzerland)
2024

Cystinosis Registry of India: Data Analysis of Patients with Cystinosis.

Indian journal of nephrology
2024

Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice.

Clinical kidney journal
2024

Nlrp2 deletion ameliorates kidney damage in a mouse model of cystinosis.

Frontiers in immunology
2024

Comparison of Scheimpflug Corneal Tomography and Anterior Segment Optical Coherence Tomography Measurements in Corneal Cystinosis: A Case Series.

Eye &amp; contact lens
2024

Residual Cystine Transport Activity for Specific Infantile and Juvenile CTNS Mutations in a PTEC-Based Addback Model.

Cells
2024

Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.

Molecular genetics and metabolism
2024

MFSD12 depletion reduces cystine accumulation without improvement in proximal tubular function in experimental models for cystinosis.

American journal of physiology. Renal physiology
2024

CTNS Mutations Causing Autosomal Recessive Cystinosis in a Subset of Iranian Population: Report of Two New Variants.

Advanced biomedical research
2024

Lysosomal cystine accumulation activates mTOR signaling in cystinosis: are mTOR inhibitors the cure?

Kidney international
2024

Addressing the psychosocial aspects of transition to adult care in patients with cystinosis.

Pediatric nephrology (Berlin, Germany)
2024

Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.

Pediatric nephrology (Berlin, Germany)
2024

Gene editing improves endoplasmic reticulum-mitochondrial contacts and unfolded protein response in Friedreich's ataxia iPSC-derived neurons.

Frontiers in pharmacology
2024

Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives.

Pediatric nephrology (Berlin, Germany)
2024

The Clinical Manifestations and Disease Burden of Cystinosis in Saudi Arabia: A Single-Tertiary Center Experience.

Cureus
2024

Fertility Management in Cystinosis: A Clinical Perspective.

Kidney international reports
2024

A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis.

International journal of molecular sciences
2024

Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis.

Clinical journal of the American Society of Nephrology : CJASN
2024

Renal transplantation for infantile and juvenile cystinosis: Two case report and review of the literature.

Transplant immunology
2024

Extrarenal complications of cystinosis.

Pediatric nephrology (Berlin, Germany)
2024

Neurologic involvement in cystinosis: Focus on brain lesions and new evidence of four-repeat (4R-) Tau immunoreactivity.

Journal of the neurological sciences
2023

Event-related potential (ERP) evidence for visual processing differences in children and adults with cystinosis (CTNS gene mutations).

Orphanet journal of rare diseases
2023

Studies with Human-Induced Pluripotent Stem Cells Reveal That CTNS Mutations Can Alter Renal Proximal Tubule Differentiation.

International journal of molecular sciences
2023

Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.

BMC nephrology
2023

Cystinosis: Status of research and treatment in India and the world.

Journal of biosciences
2023

Evaluation of the efficacy of cystinosin supplementation through CTNS mRNA delivery in experimental models for cystinosis.

Scientific reports
2024

Functional analysis of the CTNS gene exonic variants predicted to affect splicing.

Clinical genetics
2023

Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence.

Pharmaceutics
2024

Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective.

Pediatric nephrology (Berlin, Germany)
2023

Tubular Diseases and Stones Seen From Pediatric and Adult Nephrology Perspectives.

Seminars in nephrology
2024

Omic Studies on In Vitro Cystinosis Model: siRNA-Mediated CTNS Gene Silencing in HK-2 Cells.

Laboratory investigation; a journal of technical methods and pathology
2023

Dietary supplementation of cystinotic mice by lysine inhibits the megalin pathway and decreases kidney cystine content.

Scientific reports
2023

A Review on the Antimutagenic and Anticancer Effects of Cysteamine.

Advances in pharmacological and pharmaceutical sciences
2023

Ocular manifestations of the genetic renal tubulopathies.

Ophthalmic genetics
2023

Pattern of hereditary renal tubular disorders in Egyptian children.

The Turkish journal of pediatrics
2024

The CTNS-MTORC1 axis couples lysosomal cystine to epithelial cell fate decisions and is a targetable pathway in cystinosis.

Autophagy
2023

Fibrosing Colonopathy Presenting in a Patient with Cystinosis.

JPGN reports
2024

Multinucleated podocytes as a clue to diagnosis of juvenile nephropathic cystinosis.

Pediatric nephrology (Berlin, Germany)
2023

Rescue of Alzheimer's disease phenotype in a mouse model by transplantation of wild-type hematopoietic stem and progenitor cells.

Cell reports
2023

ER-associated degradation in cystinosis pathogenesis and the prospects of precision medicine.

The Journal of clinical investigation
2023

Event-related potential (ERP) evidence for early visual processing differences in children and adults with Cystinosis (CTNS gene mutations).

Research square
2023

Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.

Pharmaceutics
2023

Lysosomal cystine export regulates mTORC1 signaling to guide kidney epithelial cell fate specialization.

Nature communications
2023

Rickets in proximal renal tubular acidosis: a case series of six distinct etiologies.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2023

Chest configuration in children and adolescents with infantile nephropathic cystinosis compared with other chronic kidney disease entities and its clinical determinants.

Pediatric nephrology (Berlin, Germany)
2023

A different approach to cystinosis: ultrasound, doppler, and shear wave elastography findings of thyroid gland.

Orphanet journal of rare diseases
2022

A rare case of a patient with cystinosis and COVID-19 pneumonia with difficult weaning from mechanical ventilation: the "pocus force".

Journal of anesthesia, analgesia and critical care
2023

The gene therapy for corneal pathology with novel nonsense cystinosis mouse lines created by CRISPR Gene Editing.

The ocular surface
2023

Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").

Orphanet journal of rare diseases
2023

Utility of post-transplant native nephrectomy in children with nephropathic cystinosis: A single centre retrospective study.

Nephrology (Carlton, Vic.)
2023

The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.

Pediatric nephrology (Berlin, Germany)
2023

In vivo confocal microscopy for ocular surface investigation in nephropathic cystinosis.

Journal francais d'ophtalmologie
2023

Corneal cystinosis following eight years of systemic and topical treatment.

Journal francais d'ophtalmologie
2023

Event-related potential (ERP) evidence of early visual processing differences in cystinosis.

bioRxiv : the preprint server for biology
2023

Clinical significance of hypouricemia in children and adolescents.

Pediatric nephrology (Berlin, Germany)
2023

Posterior Segment Involvement in Infantile Nephropathic Cystinosis - A Review.

Klinische Monatsblatter fur Augenheilkunde
2023

[The Eye as a Window to Cystinosis].

Klinische Monatsblatter fur Augenheilkunde
2023

[Cystinosis: From the gene identification to the first gene therapy clinical trial].

Medecine sciences : M/S
2023

Nephrogenic Diabetes Insipidus in a 10-mo-old Infant: Complication of Nephropathic Cystinosis.

Indian journal of pediatrics
2023

Health-related quality of life and patient-reported outcome measurements in patients with cystinosis.

JIMD reports
2023

Schizophrenia Misdiagnosis after Capgras and Cotard Delusions in a Patient with Infantile Cystinosis, Cavum Septi Pellucidi, Cavum Vergae and Cavum Veli Interpositi.

Behavioral sciences (Basel, Switzerland)
2023

Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis.

International journal of molecular sciences
2023

Corneal Densitometry to Assess the Corneal Cystine Deposits in Patients With Cystinosis.

Cornea
2023

Inherited Fanconi syndrome.

World journal of pediatrics : WJP
2023

Corneal Manifestation in Patients with Infantile Nephropathic Cystinosis.

Klinische Monatsblatter fur Augenheilkunde
2023

Tenofovir as a cause of acquired fanconi's syndrome.

Annals of African medicine
2023

The Pitfall of White Blood Cell Cystine Measurement to Diagnose Juvenile Cystinosis.

International journal of molecular sciences
2022

Dual Molecular Diagnoses of Recessive Disorders in a Child from Consanguineous Parents: Case Report and Literature Review.

Genes
2023

Thermo-responsive and mucoadhesive gels for the treatment of cystinosis.

Biomaterials advances
2023

The TGM2 inhibitor cysteamine hydrochloride does not impact corneal epithelial and stromal wound healing in vitro and in vivo.

Experimental eye research
2023

Accelerated Corneal Crosslinking for Treatment of Keratoconus in Children and Adolescents under 18 Years of Age.

Klinische Monatsblatter fur Augenheilkunde
2022

Cystinosis: a rare multisystem disease.

Polish archives of internal medicine
2022

A new proof of evidence of cysteamine quantification for therapeutic drug monitoring in patients with cystinosis.

Orphanet journal of rare diseases
2022

Presumed Bietti crystalline dystrophy with optic nerve head drusen: a case report.

Journal of medical case reports
2023

Reliability analysis of successive Corvis ST® measurements in keratoconus 2 years after accelerated corneal crosslinking compared to untreated keratoconus corneas.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2023

Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine.

Human molecular genetics
2022

Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.

Pharmaceutics
2022

Metabolic Advantage of 25(OH)D3 versus 1,25(OH)2D3 Supplementation in Infantile Nephropathic Cystinosis-Associated Adipose Tissue Browning and Muscle Wasting.

Cells
2023

A novel variant in GATM causes idiopathic renal Fanconi syndrome and predicts progression to end-stage kidney disease.

Clinical genetics
2022

Dermal Cystine Crystals: An Incidental Finding During Mohs Surgery.

The American Journal of dermatopathology
2023

Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.

Journal of inherited metabolic disease
2022

In vitro activity of cysteamine against SARS-CoV-2 variants.

Molecular genetics and metabolism
2022

Structure and mechanism of human cystine exporter cystinosin.

Cell
2022

Young Adults With Hereditary Tubular Diseases: Practical Aspects for Adult-Focused Colleagues.

Advances in chronic kidney disease
2022

Cysteamine affects skeletal development and impairs motor behavior in zebrafish.

Frontiers in pharmacology
2022

Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients.

Clinical kidney journal
2022

Gastrointestinal Manifestations of Adult Cystinosis in Iran: A Descriptive Study.

Medical journal of the Islamic Republic of Iran
2022

Nephropathic cystinosis in Poland: a 40-year retrospective study.

Polish archives of internal medicine
2022

Structural basis for proton coupled cystine transport by cystinosin.

Nature communications
2022

Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.

Molecular genetics and metabolism
2022

Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.

Molecular genetics and metabolism
2022

Pregnancy and Breastfeeding in Nephropathic Cystinosis With Native Kidneys.

Kidney international reports
2022

A Successful Adolescent Pregnancy in a Patient With Cystinosis and CKD Not Yet on Kidney Replacement Therapy.

Kidney international reports
2022

Ocular biodistribution of cysteamine delivered by a sustained release microsphere/thermoresponsive gel eyedrop.

International journal of pharmaceutics
2022

Importance of adherence to topical cysteamine in infantile ocular cystinosis: An illustrative case.

Indian journal of ophthalmology
2022

Pregnancy in cystinosis patients with chronic kidney disease: A European case series.

Journal of inherited metabolic disease
2022

Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis.

Orphanet journal of rare diseases
Ver todos os 1.215 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Cistinose.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Cistinose

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. A Refined Method for Micro-Scale Blood Cystine Measurement in Preclinical Cystinosis Models.
    International journal of molecular sciences· 2026· PMID 41751789mais citado
  2. Advances in Pharmacological Treatments for Cystinosis: Cysteamine and Its Alternatives.
    ACS pharmacology &amp; translational science· 2026· PMID 41710743mais citado
  3. Hematopoietic Stem-Cell Gene Therapy for Cystinosis.
    The New England journal of medicine· 2026· PMID 41707137mais citado
  4. Cystinosis and Cellular Energy Failure: Mitochondria at the Crossroads.
    International journal of molecular sciences· 2026· PMID 41596280mais citado
  5. Genetic predisposition to porto-sinusoidal vascular disorder.
    Hepatology (Baltimore, Md.)· 2026· PMID 38900412mais citado
  6. A novel gene therapy approach for nephropathic cystinosis.
    Nat Rev Nephrol· 2026· PMID 41917490recente
  7. Clinical, biochemical, and molecular spectrum of nephropathic cystinosis: Two novel CTNS mutations.
    Saudi J Kidney Dis Transpl· 2026· PMID 41914990recente
  8. A behavioral and electrophysiological investigation of conflict monitoring in cystinosis (CTNS gene mutations) using the flanker paradigm.
    Front Nephrol· 2026· PMID 41908583recente
  9. Intracranial Hypertension in Nephropathic Cystinosis: A Paediatric Case and Literature Review.
    J Paediatr Child Health· 2026· PMID 41889018recente
  10. Cystinosin regulates Na(+)/H(+) exchanger 3 trafficking and function in kidney proximal tubular cells.
    EMBO Rep· 2026· PMID 41876818recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:213(Orphanet)
  2. MONDO:0016239(MONDO)
  3. GARD:6236(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q1149042(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Cistinose
Compêndio · Raras BR

Cistinose

ORPHA:213 · MONDO:0016239
Prevalência
1-9 / 100 000
Herança
Autosomal recessive
CID-10
E72.0 · Distúrbios do transporte de aminoácidos
CID-11
Ensaios
14 ativos
Medicamentos
1 registrados
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
1.5 (Europe)
MedGen
UMLS
C0010690
Repurposing
1 candidato
cysteaminetissue transglutaminase inhibitor
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades